Sukhatme Mayukh 4
4 · Roivant Sciences Ltd. · Filed Dec 26, 2024
Insider Transaction Report
Form 4
Sukhatme Mayukh
DirectorPresident & CIO
Transactions
- Sale
Common Shares
2024-12-24$12.00/sh−185,946$2,231,352→ 18,836,547 total - Sale
Common Shares
2024-12-26$12.01/sh−689,495$8,280,835→ 18,836,547 total - Exercise/Conversion
Common Shares
2024-12-23$3.85/sh+10,796$41,565→ 18,847,343 total - Exercise/Conversion
Common Shares
2024-12-24$3.85/sh+185,946$715,892→ 19,022,493 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-26−689,495→ 15,224,363 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (689,495 underlying) - Exercise/Conversion
Common Shares
2024-12-26$3.85/sh+689,495$2,654,556→ 19,526,042 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-23−10,796→ 16,099,804 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (10,796 underlying) - Sale
Common Shares
2024-12-23$12.00/sh−10,796$129,552→ 18,836,547 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-24−185,946→ 15,913,858 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (185,946 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).